July 27, 2021
FOIA For Staff Lists and Leadership Directories
Transparency surrounding the identities of the country’s senior-most political leaders should be a given. Unfortunately, the federal government presently falls short in this regard. Inconsistent and insufficient standards for publishing and maintaining leadership and senior staff directories makes it difficult, if not impossible, to learn who occupies hundreds of critical roles throughout the federal government.
July 27, 2021 | Washington Monthly
Crypto is a global phenomenon, and one with a rapidly growing capacity to upend tax administration worldwide. The U.S. has been slow to act to combat this threat, but clever use of extant unilateral and multilateral laws on information sharing and programs that capitalize on expertise and information outside government provide opportunities for much better protection against tax evasion. If Biden and his administration are committed to closing tax loopholes, they must use every tool available.
July 23, 2021 | American Prospect
If Biden is emerging as an anti-monopoly president, then why is he rewarding Cohen, a fixer for one of the go-to examples of monopoly power in America? More importantly, if he hopes to redeem American democracy from Trumpism, why is Biden rewarding the political strategist for a company that does not care about basic voting rights, especially for Black people?
July 23, 2021
Trump Picked A Climate-Skeptical Insurance Lobbyist For A Key Regulatory Council. Biden Hasn't Fired Him Yet.
Workman came with exactly zero experience as an insurance regulator, but plenty of experience from the opposite side of the courtroom: for 17 years, he’d been the President and CEO of the life insurance industry’s main lobbying group in the state of New York, the Life Insurance Council of New York (LICONY).
July 22, 2021
In 2019, Gallup found that the pharmaceutical industry was “the most poorly regarded industry in Americans’ eyes,” and rightfully so. Pharmaceutical companies often set drug prices exorbitantly high, including life-saving drugs which patients literally cannot go without, such as insulin. This includes older drugs that are cheaper to produce — such as epinephrine (emergency medication used to treat severe allergic reactions and asthma attacks). These firms achieve this by stifling competition at the consumer’s expense, jealously protecting their money-makers from the generics which the pharmaceutical system is supposed to develop after a patent expires.
July 20, 2021
June 30th marked the last official day of Republican Neil Chatterjee’s term as a commissioner on the Federal Energy Regulatory Commission (FERC). Despite FERC’s obscurity, it is a critically important independent agency of the federal government that regulates the interstate transmission of oil, gas, and electricity, and reviews proposals to build gas terminals and pipelines. As of July 1st, a new commissioner nominated by President Biden and confirmed by the Senate could have stepped in, giving the five-seat board a Democratic majority. Biden has thus far failed to begin that process, so Chatterjee will remain serving an expired term until Biden appoints and the Senate confirms someone new.
July 19, 2021
Graham’s history fighting for the public against the predations of and systemic risks posed by Wall Street, and now the fossil fuel industry, speaks for itself.
July 16, 2021
After months of delay, Biden is rumored to have selected a new Director of the United States Patent and Trademark Office (USPTO) acceptable to Delaware Senator Chris Coons. If true, that will mean Biden has sacrificed a critical opportunity to catalyze bold patent reform in the service of political patronage. Reports have indicated that Biden offered Coons, who expressed hope that coronavirus might be a “sword” for stronger IP protections, the power to decide the next USPTO Director as a consolation prize for not having been named Secretary of State.
July 16, 2021
Rumors that Delaware Senator Chris Coons (D-DE) has had a hand in nominating the new U.S. Patent and Trademark Office (USPTO) Director are extremely worrisome given Coons’ coziness with the Big Pharma industry and willingness to vote against his own party to benefit large corporations. Coons has a long record of proposing and passing legislation (often with far-right Republicans) to benefit Big Pharma companies, at the expense of consumers and small businesses. While harmful to the general public, Coons’ legislation has directly benefited his family’s medical device manufacturer, enriching himself. His record and blatant disregard for consumer welfare should exclude him from any conversations about executive branch personnel.
July 14, 2021
GOP Cries Foul As Biden Seizes on the Supreme Court’s New Precedent
After months focused on the infrastructure bill, the Biden administration appears to be leaning into bold, executive action once again. On Friday, the President signed an executive order directing a dozen different agencies to take specific steps to promote competition. Many heralded the move as the start of a new trust-busting era.
July 14, 2021
The Biden Administration has a historic opportunity to reverse the executive branch’s long-standing war on whistleblowers, and end the all-too-common (and sadly bipartisan) practice of villainizing whistleblowers and leakers to avoid accountability for government wrongdoing revealed by these actors.
July 13, 2021
As of this writing, the Biden Administration has yet to announce a pick for director of the U.S. Patent and Trademark Office. As Fatou Ndiaye has pointed out, this is likely due to behind-the-scenes tension between patent hawks in the Democratic caucus, specifically Senator Chris Coons (D-DE), and the broader progressive, reformist forces in the administration that made it possible for the United States to back a waiver on obligations under the Trade-Related Aspects of Intellectual Property Rights.